^
Association details:
Biomarker:BRAF mutation
Cancer:Rectal Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Excerpt:
...An ARMS-PCR proven KRAS, NRAS mutation, excluding BRAF mutation or microsatellite instablility-High; 3....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Neoadjuvant Chemotherapy plus Bevacizumab Combined with Total Mesorectal Excision in Treating Locally Advanced Rectal Cancer Patients with BRAF Mutation: Clinical Benefit and Safety

Published date:
12/09/2021
Excerpt:
To investigate clinical benefit and safety of neoadjuvant chemotherapy (NAC) plus bevacizumab combined with total mesorectal excision (TME) in treating patients with BRAF-mutated locally advanced rectal cancer (LARC)….Patients in the control group received a standard treatment regimen of TME combined with NAC (n = 45), and patients in the observation group received NAC plus bevacizumab combined with TME (n = 55)....In terms of long-term clinical benefit, the RFS of patients in the observation group was evidently longer (p = 0.037) than that in the control group.
Secondary therapy:
Chemotherapy
DOI:
10.1155/2021/4227650